Inactivation of the p16 Cyclin-Dependent Kinase Inhibitor in High-Grade Canine Non-Hodgkin's T-Cell Lymphoma
Open Access
- 1 July 2007
- journal article
- research article
- Published by SAGE Publications in Veterinary Pathology
- Vol. 44 (4), 467-478
- https://doi.org/10.1354/vp.44-4-467
Abstract
The significance of p16/Rb tumor suppressor pathway inactivation in T-cell non-Hodgkin's lymphoma (NHL) remains incompletely understood. We used naturally occurring canine NHL to test the hypothesis that p16 inactivation has specific pathologic correlates. Forty-eight samples (22 T-cell NHL and 26 B-cell NHL) were included. As applicable, metaphase- or array-based comparative genomic hybridization, Southern blotting, promoter methylation, and Rb phosphorylation were used to determine the presence, expression, and activity of p16. Fisher's exact test was used to test for significance. Deletion of p16 (or loss of dog chromosome 11) was restricted to high-grade T-cell NHL (lymphoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified). These were characterized by a concomitant increase of tumor cells with Rb phosphorylation at canonical CDK4 sites. Rb phosphorylation also was seen in high-grade B-cell NHL (diffuse large B-cell lymphoma and Burkitt-type lymphoma), but in those cases, it appeared to be associated with c-Myc overexpression. The data show that p16 deletion or inactivation occurs almost exclusively in high-grade T-cell NHL; however, alternative pathways can generate functional phenotypes of Rb deficiency in low-grade T-cell NHL and in high-grade B-cell NHL. Both morphologic classification according to World Health Organization criteria and assessment of Rb phosphorylation are prognostically valuable parameters for canine NHL.Keywords
This publication has 39 references indexed in Scilit:
- CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin LymphomaVeterinary Pathology, 2005
- Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphomaCancer, 2005
- G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expressionLeukemia, 2005
- Commitment Point during G0→G1 That Controls Entry into the Cell CycleMolecular and Cellular Biology, 2003
- Molecular etiology of mature T-cell non-hodgkins lymphomasFrontiers in Bioscience-Landmark, 2003
- Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphomaLeukemia, 2000
- Identification of CDK4 as a target of c-MYCProceedings of the National Academy of Sciences of the United States of America, 2000
- Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27The EMBO Journal, 1999
- Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescenceOncogene, 1998
- DNA Methylation Is Not Involved in Growth Regulation of Gene Expression of Proliferating Cell Nuclear AntigenExperimental Cell Research, 1993